Recombinant Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] (ab200827)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR15657] to Androgen receptor variant 5,6,7es
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Androgen receptor variant 5,6,7es antibody [EPR15657]
See all Androgen receptor variant 5,6,7es primary antibodies -
Description
Rabbit monoclonal [EPR15657] to Androgen receptor variant 5,6,7es -
Host species
Rabbit -
Specificity
This ARv567es antibody (Ab200827, clone EPR15657) is a rabbit monoclonal antibody against Human Androgen receptor variant 5,6,7es (aa 700 to the C-terminus). This antibody does not react with AR-FL. -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: M12-3FARV567es. IHC-P: Human prostate cancer tissue.
-
General notes
Anti-ARv567es RabMAb product (Clone EPR15657) has been highlighted in the following poster: Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody.
For ARv7 specific RabMAb antibody - see ab198394.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR15657 -
Isotype
IgG
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Corresponding Antibody
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab200827 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 100 kDa (predicted molecular weight: 77 kDa).
It is suggested to use the low dilution in natural material as 1/10,000 is based on over-expressed lysate testing. |
|
IHC-P |
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 100 kDa (predicted molecular weight: 77 kDa). It is suggested to use the low dilution in natural material as 1/10,000 is based on over-expressed lysate testing. |
IHC-P
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Cellular localization
Nuclear -
Database links
- SwissProt: D2KF13 Human
-
Alternative names
- Androgen receptor splice variants antibody
- AR antibody
- AR-FL antibody
see all
Images
-
Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic and nuclear staining on Human prostate cancer tissue is observed. Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
All lanes : Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] (ab200827) at 1/1000 dilution
Lane 1 : Human fetal liver tissue lysate
Lane 2 : PC-3 (Human prostate adenocarcinoma cell line) whole cell lysate
Lane 3 : LNCaP (Human prostate cancer cell line) whole cell lysate
Lane 4 : T-47D (Human ductal breast epithelial tumor cell line) whole cell lysate
Lane 5 : Human prostate tissue lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 77 kDa
Exposure time: 3 minutesBlocking/Dilution buffer: 5% NFDM/TBST.
-
Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] (ab200827) at 1/10000 dilution + M12-3FARV567es
Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 77 kDa
Observed band size: 100 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking/Dilution buffer: 5% NFDM/TBST.
Full length ARV567es M12 overexpress lysate containing aa1-739 with 3× DDDDK-tag was supplied by Stephen R. Plymate, M.D. Professor, Department of Medicine, University of Washington, Seattle, WA.
Liu G. et al. 2013. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15, 1009-1017.
Cao B. et al. 2014. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646-1656.
-
Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic and nuclear staining on Human prostate cancer tissue is observed. Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Negative on Human prostate cancer. Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Androgen receptor variant 5,6,7es with ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Negative on Human liver tissue. Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (4)
ab200827 has been referenced in 4 publications.
- Wang R et al. N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells. Cell Death Dis 13:626 (2022). PubMed: 35853851
- Shaw J et al. Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay. Sci Rep 8:163 (2018). PubMed: 29317749
- Shan X et al. Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer. PeerJ 6:e4661 (2018). PubMed: 29682426
- Shan X et al. Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer. PeerJ 3:e1232 (2015). WB . PubMed: 26401448